I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| hepatocyte | 5 studies | 68% ± 26% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| hepatocyte | 5 studies | 68% ± 26% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| liver | 3 studies | 42% ± 17% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| liver | 100% | 72732.71 | 226 / 226 | 93% | 324.92 | 376 / 406 |
| breast | 92% | 3235.85 | 422 / 459 | 37% | 46.60 | 411 / 1118 |
| pancreas | 86% | 16.13 | 282 / 328 | 7% | 0.21 | 13 / 178 |
| lung | 81% | 19.49 | 468 / 578 | 5% | 0.14 | 52 / 1155 |
| spleen | 80% | 166.31 | 193 / 241 | 0% | 0 | 0 / 0 |
| kidney | 76% | 11.10 | 68 / 89 | 2% | 0.47 | 14 / 901 |
| adrenal gland | 76% | 10.50 | 197 / 258 | 1% | 0.02 | 2 / 230 |
| brain | 66% | 8.11 | 1732 / 2642 | 5% | 0.10 | 37 / 705 |
| thymus | 68% | 8.40 | 443 / 653 | 1% | 0.01 | 4 / 605 |
| prostate | 63% | 8.30 | 155 / 245 | 0% | 0.00 | 1 / 502 |
| adipose | 61% | 29.25 | 737 / 1204 | 0% | 0 | 0 / 0 |
| intestine | 60% | 36.00 | 577 / 966 | 0% | 0.64 | 2 / 527 |
| ovary | 54% | 7.08 | 98 / 180 | 0% | 0 | 0 / 430 |
| stomach | 48% | 5.43 | 173 / 359 | 1% | 0.05 | 4 / 286 |
| peripheral blood | 49% | 52.18 | 453 / 929 | 0% | 0 | 0 / 0 |
| uterus | 45% | 7.32 | 77 / 170 | 1% | 0.16 | 3 / 459 |
| bladder | 43% | 5.52 | 9 / 21 | 1% | 0.04 | 6 / 504 |
| skin | 33% | 8.75 | 591 / 1809 | 1% | 0.01 | 3 / 472 |
| esophagus | 32% | 4.33 | 462 / 1445 | 1% | 0.02 | 2 / 183 |
| blood vessel | 31% | 4.18 | 416 / 1335 | 0% | 0 | 0 / 0 |
| heart | 24% | 7.64 | 203 / 861 | 0% | 0 | 0 / 0 |
| muscle | 22% | 2.61 | 175 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0071548 | Biological process | response to dexamethasone |
| GO_0006536 | Biological process | glutamate metabolic process |
| GO_0006103 | Biological process | 2-oxoglutarate metabolic process |
| GO_0006559 | Biological process | L-phenylalanine catabolic process |
| GO_0009058 | Biological process | biosynthetic process |
| GO_0006979 | Biological process | response to oxidative stress |
| GO_0046689 | Biological process | response to mercury ion |
| GO_0006572 | Biological process | tyrosine catabolic process |
| GO_0005575 | Cellular component | cellular_component |
| GO_0005829 | Cellular component | cytosol |
| GO_0016597 | Molecular function | amino acid binding |
| GO_0004838 | Molecular function | L-tyrosine:2-oxoglutarate aminotransferase activity |
| GO_0042802 | Molecular function | identical protein binding |
| GO_0005515 | Molecular function | protein binding |
| GO_0030170 | Molecular function | pyridoxal phosphate binding |
| Gene name | TAT |
| Protein name | Tyrosine aminotransferase (TAT) (EC 2.6.1.5) (L-tyrosine:2-oxoglutarate aminotransferase) Tyrosine aminotransferase (TAT) (EC 2.6.1.5) |
| Synonyms | |
| Description | FUNCTION: Transaminase involved in tyrosine breakdown. Converts tyrosine to p-hydroxyphenylpyruvate. Can catalyze the reverse reaction, using glutamic acid, with 2-oxoglutarate as cosubstrate (in vitro). Has much lower affinity and transaminase activity towards phenylalanine. . FUNCTION: Transaminase involved in tyrosine breakdown. Converts tyrosine to p-hydroxyphenylpyruvate. . |
| Accessions | P17735 ENST00000355962.5 A1L4G7 |
